ChemPath: Porphyrias ✔️ Flashcards

1
Q

What is porphyria?

A
  • Disorders caused by deficiencies in enzymes of the haem synthesis pathway
  • Deficiency can be partial or complete
  • This leads to the accumulation of toxic haem precursors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the two ways in which porphyria can manifest?

A
  • Acute neuro-visceral attacks
  • Acute or chronic cutaneous symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

List some key features of haem.

A
  • Organic heterocyclic compound with Fe2+ in the centre
  • There is a terapyrrole ring around the iron
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Which cells produce haem?

A

Aminolevulinic acid synthase (ALA synthase) –> found in all cells to produce haem

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Where is haem found?

A

Erythroid cells

Liver cytochrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Draw the haem synthesis pathway.

A

Blue rectangle = processes within the mitochondria
* succinyl CoA + glycine produces 5-ALA using ALA synthase
* 5-ALA leaves mitochondria and two of them join together to make PBG using PBG synthase
* PBG is converted to HMB using HMB synthase
* HMB then produces 1 of 2 products (uroporphyrinogen I and III)
* Uroporphyrinogen III is important for haem synthesis: as uroporphyrinogen III is converted to coproporhyrinogen III and then taken up by the mitochondria to form protoporphyrinogen IX –>protoporphyrin IX –> HAEM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What can an enzyme deficiency in the haem pathway cause?

A
  • 7 enzymes in the pathway, any of which can be affected to cause porphyria (build up of porphyrins). There are 3 porphyria presentations.
  • Therefore, enzyme deficiencies can cause build up of 5-ALA, PBG, or any of the porphyrinogens
  • This build up can cause them to go via alternative pathways and build up other toxic/waste products
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which component of the haem biosynthesis pathway is neurotoxic?

A

5-ALA –> CAUSES NEUROVISCERAL SYMPTOMS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What types of porphyrin may be produced in the absence of iron?

A
  • Metal-free protoporphyrins
  • Zinc protoporphyrin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How can porphyrias be classified?

A

Principle site of enzyme deficiency:

  • Erythroid
  • Hepatic

Clinical presentation:

  • Acute VS non-acute
  • Neurovisceral (acute) or cutaneous skin lesions (non-acute)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the enzyme deficiencies and consequent presentations of porphyria?

A

7 enzymes in the pathway, of which any 7 can be affected.
THREE presentations:
1. Neurovisceral
2. Blistering cutaneous symptoms
3. Non-blistering cutaneous symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Outline the relationships between UV light and skin lesions.

A

Porphyrinogens are oxidised and then activated by UV light into activated porphyrins as double bonds are formed.

NOTE: porphyrinogens do NOT oxidise in cells due to low availability of O2 in cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is a key difference between porphyrinogens and porphyrins?

A
  • Porphyrinogens - (PRECURSORS to porphyrins) colourless, unstable and readily oxidised to porphyrin
  • Porphyrins - highly coloured

NOTE: porphúra means purple in Greek

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which porphyrins appears in the urine and faeces?

A
  • Urine - uroporphyrins are water soluble
  • Faeces - coproporphyrins are less soluble and near the end of the pathway

NOTE: someone with porphyria will have colourless/yellow urine which turns red/dark red/purple as the porphyrinogens are oxidised and activated into porphyrins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

List four types of ACUTE porphyria and the enzymes involved.

A
  • Plumboporphyria - PBG synthase
  • Acute intermittent porphyria (AIP) - HMB synthase / PBG deaminase (2nd most common)
  • Hereditary coproporphyria (HCP) - coproporphyrinogen oxidase
  • Variegate porphyria (VP) - protoporphyrinogen oxidase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

List three types of NON-ACUTE porphyria and the enzymes involved.

A
  • Congenital erythropoietic porphyria - uroporphyrinogen III synthase
  • Porphyria cutanea tarda - uroporphyginogen decarboxylase –> MOST COMMON!
  • Erythropoietic protoporphyria - ferrochetolase (3rd most common in general, most common in children)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the most common type of porphyria?

A

Porphyria cutanea tarda

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the most common type of porphyria in children?

A

Erythropoietic protoporphyria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What does ALA synthase deficiency cause?

A

X-linked
Causes sideroblastic anaemia
Does NOT cause any porphyria

20
Q

How can a mutation in ALA synthase lead to porphyria?

A

A gain-of-function mutation will results in increased throughput through the pathway leading to a build-up in protoporphyrin IX as it overwhelms the ability of ferrochetolase to convert it into haem.

21
Q

What are the main features of PBG synthase deficiency (also called ALA dehydratase deficiency) ?

A
  • Causes acute porphyria
  • Leads to accumulation of ALA
    Neurovisceral symptoms:
  • Abdominal pain (MOST IMPORTANT feature)
  • Neurological symptoms (e.g. coma, bulbar palsy, motor neuropathy)
22
Q

Which deficiency causes acute intermittent porphyria (AIP)?

A

HMB synthase (aka PBG deaminase)

23
Q

Outline the clinical features of acute intermittent porphyria (AIP).

A
  • Rise in PBG and ALA
  • Autosomal dominant
  • Neurovisceral attacks:
    • Abdominal pain
    • Tachycardia and hypertension
    • Constipation, urinary incontinence
    • Hyponatraemia and seizures
    • Sensory loss/muscle weakness
    • Arrythmias/cardiac arrest

Important: there are NO skin symptoms (because no porphyrinogens are produced)

NOTE: 90% will be asymptomatic

24
Q

How do AIP attacks come about?

A

Normally, enzyme activity rests at 50% of normal
Therefore 90% remain asymptomatic
BUT, precipitating factors can then cause AIP attacks e.g.
* DRUGS (most common) –> ALA synthase inhibitors e.g. steroids, ethanol, anticonvulsants (AKA CYP450 inducers)
* Stress (infection, surgery)
* Reduced caloric intake
* Endocrine factors

25
Q

List some precipitating factors for acute intermittent porphyria (AIP).

A
  • ALA synthase inhibitors (e.g. steroids, ethanol, anticonvulsants (CYP450 inducers))
  • Stress (infection, surgery)
  • Reduced caloric intake
  • Endocrine factors
26
Q

Describe how acute intermittent porphyria is diagnosed.

A
  • increased urinary PBG (and ALA)
  • PBG gets oxidised to porphobilin
  • Decreased HMB synthase activity in erythrocytes
27
Q

How is acute intermittent porphyria managed?

A
  • Avoid attacks (adequate nutrition, avoid precipitant drug, prompt treatment of other illnesses)
  • IV haem arginate –> IMMEDIATE treatment! (switches off haem synthesis through negative feedback)
  • IV carbohydrate (inhibits ALA synthase)
28
Q

Name two acute porphyrias that have skin manifestations. State the enzymes affected.

A
  • Hereditary coproporphyria - coproporphyrinogen oxidase
  • Variegate porphyria - protoporphyrinogen oxidase
29
Q

What is the negative consequence of accumulation of coproporphyrinogen III and protoporphyrinogen IX as a result of hereditary coproporphyria (coproporphyrinogen oxidase) and variegate porphyria (protoporphyrinogen oxidase)?

A
  • They are potent inhibitors of HMB synthase
  • Results in the accumulation of PBG and ALA –> this will lead to neurovisceral symptoms!
30
Q

What are the main clinical features of hereditary coproporphyria (HCP)?

A
  • Autosomal dominant
  • ACUTE neurovisceral attacks (due to coproporphyrinogen III build-up being potent inhibitors of HMB synthase = accumulation of PBG and ALA)
  • Skin lesions (blistering, skin fragility, classically on the backs of the hands that tend to appear hours/days after sun exposure)
31
Q

What are the main clinical features of variegate porphyria (VP)?

A
  • Autosomal dominant
  • ACUTE neurovisceral attacks (due toprotoporphyrinogen IX build-up being potent inhibitors of HMB synthase = accumulation of PBG and ALA)
  • Skin lesions (blistering, skin fragility, classically on the backs of the hands that tend to appear hours/days after sun exposure)
32
Q

What are the main clinical features of variegate porphyria?

A
  • Autosomal dominant
  • Acute attacks with skin lesions
33
Q

Investigations to differentiate between the acute porphyrias:

A
  1. CLINICAL DIAGNOSIS:
    AIP –> NO skin lesions
    HCP + VP –> YES skin lesions (blistering, back of the hand)
  2. URINE:
    Urine PBG raised in all 3 (AIP, HCP + VP)
    Urine porphyrins raised in HCP + VP only (but not AIP)
  3. FAECES:
    Faeces porphyrins raised in HCP + VP only (but not AIP)

Enzyme activity variable for all
DNA definitive but large number of mutations

34
Q

How is the porphyrin level in the urine and faeces different in hereditary coproporphyria (HCP) and variegate porphyria (VP) compared to acute intermittent porphyria (AIP)?

A
  • AIP - normal
  • HCP and VP - high

NOTE: DNA analysis offers a definitive diagnosis

35
Q

What is a common feature of NON-ACUTE porphyria?

A

Only present with skin lesions with NO neurovisceral manifestations

36
Q

List the enzymes associated with NON-ACUTE porphyria.

A
  • Uroporphyrinogen III synthase - congenital erythropoietic porphyria (CEP)
  • Uroporphyrinogen decarboxylase - porphyria cutanea tarda (PCT)
  • Ferrochetolase - erythropoietic protoporphyria (EPP)
37
Q

What is the main clinical feature of NON-ACUTE porphyria?

A
  • Skin blisters, fragility, pigmentations and erosions in sun-exposed areas
  • Occuring hours to days after sun exposure
38
Q

What are the key features of erythropoietic protoporphyria EPP)?

A
  • NON-blistering and presents with photosensitivity, burning, itching, oedema following sun exposure
  • Seen in CHILDREN
  • Photosensitivity lesions only, NO BLISTERING
  • Management = sun avoidance
39
Q

What is a key investigation for erythropoietic protoporphyria (EPP)?

A

RBC protoporphyrin

NOTE: only RBCs are affected THEREFORE only need to measure RBC protoporphyrin

40
Q

What are the causes and key features of porphyria cutanea tarda (PCT)?

A
  • Can be inherited or acquired
  • Uroporphyrinogen decarboxylase deficiency
  • Aquired causes = liver disease (Hep B, HIV, cirrhosis), drugs
  • Leads to formation of vesicles on sun-exposed areas of skin crusting, superficial scarring and pigmentation
41
Q

Outline the biochemistry features of porphyria cutanea tarda (PCT).

A
  • Urine/plasma uroporphyrins and coproporphyrins are raised
  • Ferritin is often increased
42
Q

Which drug can trigger porphyria cutanea tarda (PCT)?

A

Hexachlorobenzene

43
Q

What haematological condition are erythropoietic protoporphyria and congenital erythropoietic porphyria associated with?

A

Myelodysplastic syndromes

44
Q

During acute porphyria, what is the most useful sample to send?

A

Urine!! –> detect PBG & porphyrins:
* Urine PBG raised in all 3 (AIP, HCP + VP)
* Urine porphyrins raised in HCP + VP only (but not AIP)

NOTE: protect urine sample from light as light break down the porphyrins leading to a false negative

45
Q

Diagnostic approach diagram for porphyria:

A
  1. Is it acute –> then send urine sample
  2. Look for skin lesions
  3. Assess photosensitivity